AU2016235483A1 - Organic compounds - Google Patents

Organic compounds Download PDF

Info

Publication number
AU2016235483A1
AU2016235483A1 AU2016235483A AU2016235483A AU2016235483A1 AU 2016235483 A1 AU2016235483 A1 AU 2016235483A1 AU 2016235483 A AU2016235483 A AU 2016235483A AU 2016235483 A AU2016235483 A AU 2016235483A AU 2016235483 A1 AU2016235483 A1 AU 2016235483A1
Authority
AU
Australia
Prior art keywords
disease
net
sert
disorder
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016235483A
Other languages
English (en)
Inventor
Peng Li
Lawrence P. Wennogle
Jun Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of AU2016235483A1 publication Critical patent/AU2016235483A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2016235483A 2015-03-20 2016-03-18 Organic compounds Abandoned AU2016235483A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562135915P 2015-03-20 2015-03-20
US62/135,915 2015-03-20
PCT/US2016/023198 WO2016154027A1 (en) 2015-03-20 2016-03-18 Organic compounds

Publications (1)

Publication Number Publication Date
AU2016235483A1 true AU2016235483A1 (en) 2017-10-12

Family

ID=56977765

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016235483A Abandoned AU2016235483A1 (en) 2015-03-20 2016-03-18 Organic compounds

Country Status (13)

Country Link
US (1) US10188758B2 (enExample)
EP (1) EP3270920B1 (enExample)
JP (1) JP6726200B2 (enExample)
KR (1) KR20170129906A (enExample)
CN (1) CN107405339A (enExample)
AU (1) AU2016235483A1 (enExample)
BR (1) BR112017020135A2 (enExample)
CA (1) CA2978668A1 (enExample)
ES (1) ES2819833T3 (enExample)
IL (1) IL254320A0 (enExample)
MX (1) MX2017012022A (enExample)
RU (1) RU2017134796A (enExample)
WO (1) WO2016154027A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3339304A1 (en) 2016-12-20 2018-06-27 Laboratorios del Dr. Esteve, S.A. Quinoline and isoquinoline derivatives for treating pain and pain related conditions
EP3339307A1 (en) * 2016-12-20 2018-06-27 Laboratorios del Dr. Esteve, S.A. Nitrogen containing bicyclic derivatives for treating pain and pain related conditions
CN113195489A (zh) * 2018-11-02 2021-07-30 埃斯特韦制药股份公司 用于治疗疼痛和疼痛相关病症的新的烷氧基氨基吡啶衍生物
EP3873902A1 (en) * 2018-11-02 2021-09-08 Esteve Pharmaceuticals, S.A. New tetrahydropyrimidodiazepin and tetrahydropyridodiazepin compounds for treating pain and pain related conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU709704B2 (en) * 1995-07-24 1999-09-02 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
AU2003287023A1 (en) * 2002-11-05 2004-06-03 Eli Lilly And Company 3-aryloxy/ thio-2, 3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake
EA200601798A1 (ru) * 2004-04-30 2007-04-27 Уорнер-Ламберт Компани Ллс Замещенные соединения морфолина для лечения расстройств центральной нервной системы
WO2007010082A1 (en) * 2005-07-15 2007-01-25 Fermion Oy Process for preparing a 3-aryloxy-3-arylpropylamine
CA2661187A1 (en) * 2006-08-23 2008-02-28 Pfizer Products Inc. Piperidine derivatives
EP2161998B1 (en) * 2007-06-04 2015-09-02 Intra-Cellular Therapies, Inc. Pyridine derivatives as NET/SERT modulators
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
US9352218B2 (en) 2009-04-21 2016-05-31 Nintendo Co., Ltd. Game apparatus and computer-readable storage medium

Also Published As

Publication number Publication date
IL254320A0 (en) 2017-11-30
EP3270920B1 (en) 2020-06-17
BR112017020135A2 (pt) 2018-05-29
EP3270920A4 (en) 2018-10-24
RU2017134796A (ru) 2019-04-04
KR20170129906A (ko) 2017-11-27
ES2819833T3 (es) 2021-04-19
US20180099060A1 (en) 2018-04-12
WO2016154027A1 (en) 2016-09-29
MX2017012022A (es) 2018-01-30
JP2018508556A (ja) 2018-03-29
US10188758B2 (en) 2019-01-29
CN107405339A (zh) 2017-11-28
CA2978668A1 (en) 2016-09-29
EP3270920A1 (en) 2018-01-24
JP6726200B2 (ja) 2020-07-22

Similar Documents

Publication Publication Date Title
JP6964450B2 (ja) 造影剤の合成および使用のための組成物、方法およびシステム
CN110248655B (zh) 精神药剂及其用途
EP3828174A1 (en) Pyridazinone derivative
KR20090004950A (ko) 효소 억제제
EP3270920B1 (en) Organic compounds
JP2013532657A (ja) 環式ｎ，ｎ’−ジアリールチオ尿素及びｎ，ｎ’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
EP3418277B1 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
WO2023049480A1 (en) Substituted phenylalkylamines
EP2161998B1 (en) Pyridine derivatives as NET/SERT modulators
US10081600B2 (en) 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof
WO2015092720A1 (en) Metabolites of sonidegib (lde225)
JP2010509250A (ja) 新規な２−アミノ−ピリジン誘導体及びカリウムチャネルモジュレーターとしてのその使用
JP2010509249A (ja) 新規な４−アミノ−ピリジン誘導体及びカリウムチャネルモジュレーターとしてのその使用
EP3587398A1 (en) Novel selective ligand for dopamine d3 receptor, preparation method therefor, and pharmaceutical application thereof
US20250195699A1 (en) Radiolabeled Mu Opioid Antagonist and Methods of Making and Using the Same
US20250340562A1 (en) Chromane imaging ligands
US20220118117A1 (en) Modulators of metabotropic glutamate receptor 4
AU2021329920A9 (en) Serotonin receptor modulators
BR122025015071A2 (pt) Agentes psicotrópicos, seus usos, e composição farmacêutica
BR112019010127B1 (pt) Agentes psicotrópicos, seus usos, e composição farmacêutica

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period